Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lisata Therapeutics (LSTA) Enterprise Value (2016 - 2026)

Lisata Therapeutics filings provide 13 years of Enterprise Value readings, the most recent being -$16.3 million for Q4 2025.

  • For the quarter ending Q4 2025, Enterprise Value rose 1.27% year-over-year to -$16.3 million, compared with a TTM value of -$16.3 million through Dec 2025, up 1.27%, and an annual FY2025 reading of -$16.3 million, up 1.27% over the prior year.
  • Enterprise Value hit -$16.3 million in Q4 2025 for Lisata Therapeutics, up from -$19.3 million in the prior quarter.
  • The five-year high for Enterprise Value was -$12.4 million in Q2 2025, with the low at -$32.7 million in Q3 2023.
  • Median Enterprise Value over the past 3 years was -$20.1 million (2023), compared with a mean of -$20.6 million.
  • The sharpest move saw Enterprise Value crashed 44.67% in 2024, then soared 56.66% in 2025.
  • Year by year, Enterprise Value stood at -$22.8 million in 2023, then grew by 27.94% to -$16.5 million in 2024, then rose by 1.27% to -$16.3 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$16.3 million, -$19.3 million, and -$12.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.